Protection of Hamsters Challenged with SARS-1 CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901

22 April 2022|Journal of Infectious Diseases

Of the earlier variants of concern, Beta was found to be peculiarly effective at avoiding immunity. This warranted testing as a possible updated vaccine protein, to protect against future strains. In this pre-clinical study, hamsters were challenged with Delta variant after being vaccinated with Beta strain. The vaccination regimen succesfully protected hamsters from Delta variant infection.


An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901

21 April 2022|Vaccines (MDPI)

Taiwan's strategy in containing COVID-19 was tremendously succesfully. This, however, made it difficult for MVC to determine how effective the vaccine was at naturally protecting against COVID-19 in the wild. That said, outside of Taiwan, COVID-19 data was already extremely robust, and validated mathematical models had been generated to predict what a vaccine's efficacy of protection might be. In this immunobridging study, the MVC vaccine was found to be 3.4 times superior to AstraZeneca.


Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial

12 April 2022|The Lancet


Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial

14 March 2022|MedRxiv

The immune response of younger generations may sometimes be quite different from adults. In this adolescent safety phase II study, the MVC vaccine was tested for safety and tolerability when using adult doses on adolescent populations. Antibody generation reached similar levels to those in young adults, and no severe adverse effects were reported.


A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

9 December 2021|MedRxiv

Immune-related treatments, like vaccines, may present difficulties in people fighting with HIV. In this phase II clinical study, the MVC vaccine was tested for safety and immunogenicity in such population. 100% of participants successfully generated antibodies against COVID-19, and no serious adverse effects were recorded.


Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern

5 November 2021|Clinical Infectious Diseases

As the pandemic evolved, new variants of concern started emerging, including the Alpha and Beta strains. In this phase I analysis, serum of participants who had been vaccinated with MVC were tested for protection against these new variants. Clinical results showed that all participants presented cross-reactivity against both Alpha and Beta strains.


Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

13 October 2021|The Lancet Respiratory Medicine

MVC's clinical phase II study done in ten medical centres and one regional hospital in Taiwan, totaling 3844 participants. After two vaccinations, no serious vaccine-related events were recorded and even fevers were rarely reported. Nonetheless, 99.8% of all participants developed up to twice more antibodies than people who had naturally recovered from COVID-19. This translates to a maximum of 90% protection against the virus.


Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study

25 June 2021|EClinicalMedicine

The first clinical phase I results where two shots of MVC vaccine were administered in different doses to test for the best results. None of the doses, even the higher ones, presented serious adverse events or fever. Additionaly, virus neutralizing activity and cellular immune response proved to be robust.


CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge

22 April 2021|Scientific Reports

An application of the adjuvanted spike antigen (S2P) MVC vaccine, where hamsters were challenged with COVID-19 virus after vaccine administration. Said hamsters were succesfully protected from viral load, lung damage and weight loss, as well as other side effects.


Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

18 November 2020|Scientific Reports

A breakthrough collaboration in response to a global health emergency, presenting the premier results of a stable spike antigen as a vaccine against COVID-19 developed in a well-known and tested subunit protein platform.